Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
Demo Company
GLOBETECH PUBLISHING LLC

Compact Benchtop System Enables Preparative Protein Purification in any Laboratory

By BiotechDaily International staff writers
Posted on 03 Dec 2013
Image: The ÄKTA start protein purification system with the Frac30 fraction collector (Photo courtesy of GE Life Sciences).
Image: The ÄKTA start protein purification system with the Frac30 fraction collector (Photo courtesy of GE Life Sciences).
A compact preparative chromatography instrument that is compatible with prepacked or user prepared columns and can be combined with fraction collectors to generate a complete protein purification system in any biotech or life sciences laboratory is now on the market.

The GE Healthcare (Chalfont St. Giles, United Kingdom) ÄKTA start is designed as a stand-alone system that combines a front-facing flow path with a user-friendly interface. The system is controlled via an intuitive touchscreen, which displays the UV curve and other run data in real-time.

ÄKTA start is compatible with all common purification techniques, including affinity and ion exchange chromatography, desalting, buffer exchange, and gel filtration. The system supports purification of tagged proteins, antibodies, untagged or native proteins, and sample clean-up applications. ÄKTA start can be operated using predefined quick-start protocols, built-in templates, or by creating custom protocols. Prepacked columns are available for common applications.

The ÄKTA start instrument can be augmented with GE Healthcare's Frac30 fraction collector for automatic protein collection, and with user-friendly UNICORN start 1.0 control software, which provides additional evaluation tools and the ability to control ÄKTA start from a computer.

Related Links:

GE Healthcare



Channels

Genomics/Proteomics

view channel
Image: An activated PTEN dimer that contains two non-mutant proteins (A) can transform the functional lipid (D) on the cellular membrane (E) into a chemical form that tunes down cancer predilection. Dimers that contain a mutated protein (B) or PTEN monomers cannot transform the functional lipid (Photo courtesy of Carnegie Mellon University).

PTEN Requires a Stable Dimer Configuration to Effectively Suppress Tumor Growth

Molecular structural analysis has shown that the PTEN (phosphatase and tensin homolog) tumor suppressor can function effectively only when two wild-type alleles are present to form a stable dimer that... Read more

Business

view channel

MS Drug Deal to Net More Than USD 1 Billion

A pharmaceutical company based in Switzerland has purchased the remaining rights to the multiple sclerosis drug Ofatumumab, which will allow it to continue development of the compound for treating relapsing remitting multiple sclerosis (RRMS) and similar autoimmune diseases. Novartis (Basel, Switzerland) recently announced... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.